Radical external-beam radiotherapy,
does it really help with Reduced prostate-cancer and all-cause mortality when added to androgen-deprivation therapy in locally advanced or high-risk nonmetastatic prostate cancer?
research showsRadical external-beam radiotherapy is graded A because adding it to androgen-deprivation therapy reduced both prostate-cancer mortality and all-cause mortality in locally advanced or high-risk nonmetastatic prostate cancer. In SPCG-7, ten-year prostate-cancer mortality fell from 23.9% to 11.9% and all-cause mortality from 39.4% to 29.6%. The independent PR.3/PR07 phase 3 trial reproduced improved overall survival, with HR 0.70, and reduced prostate-cancer death. Bowel, urinary, and sexual adverse effects remain separate from efficacy.
ads claimDescriptions can expand the result into equal survival benefit from radiotherapy alone in every risk group. The direct evidence concerns radical external-beam radiotherapy added to long-term ADT in locally advanced or high-risk nonmetastatic disease.
Useful facts when choosing a product
- Radical external-beam radiotherapy uses a linear accelerator or related system to deliver fractionated radiation to the prostate and designated targets.
- The pivotal trials compared ADT alone with ADT plus radiotherapy, not radiotherapy alone.
- SPCG-7 and PR.3/PR07 mainly enrolled locally advanced or high-risk nonmetastatic prostate cancer.
- Proctitis, diarrhea, rectal bleeding, urinary frequency or pain, urethral stricture, fatigue, sexual dysfunction, and late bowel or urinary toxicity can occur.
What the research actually shows
SPCG-7/SFUO-3 assigned 875 men to lifelong endocrine therapy alone or with radiotherapy and reported ten-year prostate-cancer mortality of 23.9% versus 11.9% and all-cause mortality of 39.4% versus 29.6%. PR.3/PR07 randomized 1,205 men and its final report found improved overall survival with added radiotherapy, HR 0.70, and fewer prostate-cancer deaths. This is a mirror relationship with verdict 1444: that verdict tests adding hormonal therapy to a radiotherapy base in RTOG 85-31, whereas this verdict tests adding radiotherapy to an ADT base in SPCG-7 and PR07, providing complementary evidence for different components.
Why this is classified as A (91)
Two independent large phase 3 randomized trials reproduced reductions in prostate-cancer and all-cause mortality from the specifically randomized addition of radiotherapy, giving A with 91 points.
Counterpoint. Modern radiotherapy is more precise than the techniques used in the trials, but this difference does not automatically establish the same effect for every contemporary regimen.
Rejudgment record. New verdict — Applied the replicated hard-outcome criterion because SPCG-7 and PR.3/PR07 directly randomized the addition of radical external-beam radiotherapy to ADT and independently reproduced reductions in prostate-cancer and all-cause mortality in large phase 3 trials
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced prostate-cancer-specific mortality | A | Independent randomized SPCG-7 and PR.3/PR07 trials consistently reduced prostate-cancer death. |
| Reduced all-cause mortality | A | Two large phase 3 trials reproduced an overall-survival benefit from added radiotherapy. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Widmark A et al. SPCG-7/SFUO-3 2009 | Open-label multicenter randomized phase 3 trial | 875 | Public, cancer-foundation, and academic support | Prostate-cancer-specific and all-cause mortality | Ten-year prostate-cancer mortality was 23.9% versus 11.9% and all-cause mortality 39.4% versus 29.6%, favoring added radiotherapy. | Key independent large hard-outcome randomized trial |
| Mason MD et al. PR.3/PR07 final report 2015 | International multicenter randomized phase 3 trial | 1,205 | Canadian and United Kingdom public cancer-trial support | Overall survival and prostate-cancer death | Added radiotherapy improved overall survival (HR 0.70, 95% CI 0.57 to 0.85) and reduced prostate-cancer death. | Replicating independent large hard-outcome randomized trial |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-23).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-23 · Corrections: none
Cite this verdict
[Chamgap] Radical external-beam radiotherapy x reduced mortality in high-risk nonmetastatic prostate cancer — Evidence Grade A·91. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/mens/radical-external-beam-radiotherapy-added-to-adt-nonmetastatic-prostate-cancer/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.